Your browser doesn't support javascript.
loading
The effectiveness of 0.5% atropine in controlling high myopia in children.
Chou, A C; Shih, Y F; Ho, T C; Lin, L L.
Afiliação
  • Chou AC; Department of Ophthalmology, National Taiwan University Hospital, Taipei, Republic of China.
J Ocul Pharmacol Ther ; 13(1): 61-7, 1997 Feb.
Article em En | MEDLINE | ID: mdl-9029440
Twenty highly myopic children (> or = -6.0 D) were treated with 0.5% atropine eyedrops once per night. Twelve subjects were initially treated with a short-acting cycloplegic agent, tropicamide (0.5%) (Group A), and the other eight subjects did not receive any myopic therapy before atropine (Group B). These cases were followed for up to five years. In Group A, the mean myopic progression rate after 0.5% atropine treatment was -0.01 +/- 0.04 D/M (Diopter/Month), which was significantly lower than that of the period during tropicamide treatment (-0.12 +/- 0.09 D/M) (p < 0.05). In Group B, the mean myopic progression rate after atropine therapy was begun was -0.04 +/- 0.06 D/M, which was also significantly slower than that of non-medication, -0.14 +/- 0.07 D/M (p < 0.05). The results suggested that 0.5% atropine is effective for slowing down myopic progression, even in highly myopic children.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Atropina / Tropicamida / Midriáticos / Miopia Tipo de estudo: Observational_studies Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: J Ocul Pharmacol Ther Assunto da revista: FARMACOLOGIA / OFTALMOLOGIA / TERAPEUTICA Ano de publicação: 1997 Tipo de documento: Article País de afiliação: China
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Atropina / Tropicamida / Midriáticos / Miopia Tipo de estudo: Observational_studies Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: J Ocul Pharmacol Ther Assunto da revista: FARMACOLOGIA / OFTALMOLOGIA / TERAPEUTICA Ano de publicação: 1997 Tipo de documento: Article País de afiliação: China